NEW YORK (GenomeWeb) – MiRxes, a Singapore-based life sciences and molecular diagnostics company, has expanded its global activities in recent weeks obtaining a CE-IVD mark for a quantitative PCR-based gastric cancer test, while establishing a US subsidiary and naming distributors to sell its products across Europe, the Middle East, and Asia.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.